ClinicalTrials.gg
CompletedNCT04068519Updated Oct 26, 2024Results posted

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

A Phase 1/2 interventional study of Tislelizumab in Advanced Solid Tumors, sponsored by BeiGene. Completed at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Dec 2016, registered Aug 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This was a dose verification, pharmacokinetic (PK) assessment of products derived from two manufacturing processes and scales (500L-FMP and 2000L-FMP; FMP: Final Manufacturing Process) and indication expansion clinical study of monoclonal antibody conducted in Chinese subjects with advanced solid tumors, with a purpose of exploring the safety, tolerability, pharmacokinetics and preliminary efficacy.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants must have or cytologically confirmed advanced or tumors (unresectable), have had progression or intolerability since last standard anti-tumor treatment, or have no standard treatment or have refused standard therapy.
  2. Participants must be able to provide archival tumor tissues (paraffin blocks or at least 10 unstained tumor specimen slides).
  3. Participants must have at least one as defined per criterion version 1.1.
  4. Participant must have adequate organ function.
  5. Females are eligible to participate in the study if they are:

    a) Non- (that is, physiologically incapable of becoming pregnant) who:

    • Has had hysterectomy
    • Has had bilateral oophorectomy
    • Has had bilateral tubal ligation or are (total cessation of menses for ≥1 year) b) Childbearing potential:
    • Must be willing to use a highly effective method of for the duration of the study, and for at least 120 days after the last dose of tislelizumab, and have a negative urine or serum pregnancy test within 7 days of the first dose of study drug.
  6. Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study.

Key Exclusion Criteria:

  1. History of severe reactions to other monoclonal antibodies (mAbs).
  2. Prior active within the previous 2 years except for the tumor under investigation in this trial, cured or locally curable cancers, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast.
  3. Prior therapies targeting or PD-L1. Active brain or . Participants with are permitted if they are asymptomatic, for example, diagnosed incidentally by brain imaging, or participants with previously treated brain metastases that are asymptomatic at screening, radiographically stable and not requiring medications for at least 4 weeks prior to the first administration of study treatment.
  4. Participants with active diseases or history of autoimmune diseases or immunodeficiency that may relapse should be excluded. Participants with following diseases are allowed to be enrolled for further screening: type I diabetes, hypothyroidism managed with hormone replacement therapy only, skin diseases not requiring systemic treatment (such as vitiligo, psoriasis or alopecia), or diseases not expected to recur in the absence of external triggering factors.
  5. Participants should be excluded if they have a condition requiring systemic treatment with either corticosteroids or other medications within 14 days of study drug administration.
  6. With uncontrollable pleural effusion, pericardial effusion or ascites requiring repeated drainage.
  7. Use of any live or attenuated vaccines within 4 weeks (28 days) prior to initiation of study therapy.
  8. Major surgical procedure (Grade 3 or 4) within the past 4 weeks (28 days) prior to study drug administration.
  9. Prior allogeneic or solid organ transplantation.

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Tislelizumab

    Tislelizumab 200 mg intravenously (IV) once every 3 weeks (21 days per cycle) until no evidence of continued clinical benefits, unacceptable toxicity, or withdrawal of informed consent at the discretion of the investigator. There were 3 parts in this study: dose verification, pharmacokinetic (PK) sub-study, and indication expansion.

    Drug: Tislelizumab

Interventions

  • Administered intravenously

    Also known as: BGB-A317

06

What researchers measure

Primary outcomes

  1. Dose Verification and PK Sub-study: Number Participants With Adverse Events

    Number of participants with adverse events (AEs) and serious adverse events (SAEs), as defined per NCI-CTCAE Version 4.03, including physical examination, electrocardiograms and laboratory assessments

    Time frame: Up to approximately 23 months

  2. Dose Verification: Recommended Dose of Tislelizumab

    Recommended dose of tislelizumab for indication cohorts based on safety and tolerability

    Time frame: Up to approximately 23 months

  3. PK Sub-study: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Tislelizumab From Two Manufacturing Processes and Scales

    Pharmacokinetics from products derived from two manufacturing scales at 500 liter and 2000 liter final manufacturing process (FMP) were evaluated

    Time frame: Predose, end of infusion, 3 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22, and Day 29 predose

  4. PK Sub-study: Area Under the Concentration-time Curve From Time 0 to 28 Days Postdose (AUC0-28d) of Tislelizumab From Two Manufacturing Processes and Scales

    Pharmacokinetics from products derived from two manufacturing scales at 500 liter and 2000 liter final manufacturing process (FMP) were evaluated

    Time frame: Predose, end of infusion, 3 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22, and Day 29 predose

  5. PK Sub-study: Maximum Observed Concentration (Cmax) of Tislelizumab From Two Manufacturing Processes and Scales

    Pharmacokinetics from products derived from two manufacturing scales at 500 liter and 2000 liter FMP were evaluated

    Time frame: Predose, end of infusion, 3 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22, and Day 29 predose

  6. Indication Expansion: Objective Response Rate

    Objective response rate (ORR) is defined as the percentage of participants who achieved objective tumor response (complete response or partial response) according to RECIST Version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.

    Time frame: Up to approximately 3 years and 5 months

Secondary outcomes

  1. Dose Verification: Area Under the Concentration-time Curve From Time 0 to 21 Days Postdose (AUC0-tau) of Tislelizumab

    Time frame: Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 and Cycle 5 (21 days per cycle)

  2. Dose Verification: Maximum Observed Concentration (Cmax) of Tislelizumab

    Time frame: Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 and Cycle 5 (21 days per cycle)

  3. Dose Verification: Predose Plasma Concentration of Tislelizumab During Multiple Dosing (Ctrough)

    Time frame: Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 and Cycle 5 (21 days per cycle)

  4. Dose Verification: Apparent Terminal Half-life of Tislelizumab (t1/2)

    Time frame: Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 and Cycle 5 (21 days per cycle)

  5. Dose Verification: Clearance (Cl)

    Time frame: Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 (21 days per cycle)

  6. Indication Expansion: Progression-free Survival (PFS)

    Progression-free survival is defined as the time from the date of first study dose to disease progression or death, whichever comes first, as determined by Investigator per RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.

    Time frame: Up to approximately 3 years and 5 months

  7. Indication Expansion: Duration of Response

    Duration of response for responders with complete or partial response is defined as the time interval between the date of the earliest qualifying response and the date of progressive disease or death for any cause, whichever occurs earlier as determined by Investigator per RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.

    Time frame: Up to approximately 3 years and 5 months

  8. Indication Expansion: Clinical Benefit Rate

    Clinical benefit rate is defined as the percentage of participants in specific tumor types reaching confirmed CR, PR and durable stable disease (SD; at ≥ 24 weeks) in accordance with RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.

    Time frame: Up to approximately 3 years and 5 months

  9. Indication Expansion: Overall Survival

    Overall survival is defined as the time from the date of the first study dose to death. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.

    Time frame: Up to approximately 3 years and 5 months

  10. Indication Expansion: Disease Control Rate

    Disease control rate is defined as the percentage of participants reaching CR, PR, and SD according to RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.

    Time frame: Up to approximately 3 years and 5 months

  11. Number of Participants With Positive Anti-drug Antibody (ADA) Status to Tislelizumab

    Time frame: Up to approximately 23 months

07

Results

Posted Nov 30, 2023

Participant flow

A total of 300 participants were treated with at least 1 dose of tislelizumab. This was a single arm study with 3 parts: dose verification, pharmacokinetic (PK) sub-study, and indication expansion.

Dose Verification
Participant flow — Dose Verification
MilestoneTislelizumab
Started20
Completed4
Not completed16
Withdrew: Death15
Withdrew: Withdrawal by subject1
Pharmacokinetic Sub-study
Participant flow — Pharmacokinetic Sub-study
MilestoneTislelizumab
Started57
Completed16
Not completed41
Withdrew: Death35
Withdrew: Withdrawal by subject1
Withdrew: Lost to follow-up4
Withdrew: Other not specified1
Indication Expansion
Participant flow — Indication Expansion
MilestoneTislelizumab
Started223
Completed54
Not completed169
Withdrew: Death152
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up7

Outcome measures

PrimaryDose Verification and PK Sub-study: Number Participants With Adverse Events

Number of participants with adverse events (AEs) and serious adverse events (SAEs), as defined per NCI-CTCAE Version 4.03, including physical examination, electrocardiograms and laboratory assessments

Time frame:
Up to approximately 23 months
Reported as:
Count of participants · Participants
Dose Verification and PK Sub-study: Number Participants With Adverse Events
ParticipantsDose VerificationPK Sub-study
At least one treatment-emergent adverse event (TEAE)2054
TEAE Grade 3 of higher921
Serious adverse event414
PrimaryDose Verification: Recommended Dose of Tislelizumab

Recommended dose of tislelizumab for indication cohorts based on safety and tolerability

Time frame:
Up to approximately 23 months
Reported as:
Number · milligrams
Dose Verification: Recommended Dose of Tislelizumab
milligramsDose Verification
Dose Verification: Recommended Dose of Tislelizumab200
PrimaryPK Sub-study: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Tislelizumab From Two Manufacturing Processes and Scales

Pharmacokinetics from products derived from two manufacturing scales at 500 liter and 2000 liter final manufacturing process (FMP) were evaluated

Time frame:
Predose, end of infusion, 3 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22, and Day 29 predose
Reported as:
Geometric mean · µg/mL*day
PK Sub-study: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Tislelizumab From Two Manufacturing Processes and Scales
µg/mL*dayPK Sub-study
500L-FMP1113.9 (997.6 to 1244)
2000L-FMP1108 (985.2 to 1246)
PrimaryPK Sub-study: Area Under the Concentration-time Curve From Time 0 to 28 Days Postdose (AUC0-28d) of Tislelizumab From Two Manufacturing Processes and Scales

Pharmacokinetics from products derived from two manufacturing scales at 500 liter and 2000 liter final manufacturing process (FMP) were evaluated

Time frame:
Predose, end of infusion, 3 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22, and Day 29 predose
Reported as:
Geometric mean · µg/mL*day
PK Sub-study: Area Under the Concentration-time Curve From Time 0 to 28 Days Postdose (AUC0-28d) of Tislelizumab From Two Manufacturing Processes and Scales
µg/mL*dayPK Sub-study
500L-FMP810.2 (746.0 to 879.9)
2000L-FMP801.7 (740.8 to 867.5)
PrimaryPK Sub-study: Maximum Observed Concentration (Cmax) of Tislelizumab From Two Manufacturing Processes and Scales

Pharmacokinetics from products derived from two manufacturing scales at 500 liter and 2000 liter FMP were evaluated

Time frame:
Predose, end of infusion, 3 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22, and Day 29 predose
Reported as:
Geometric mean · µg/mL
PK Sub-study: Maximum Observed Concentration (Cmax) of Tislelizumab From Two Manufacturing Processes and Scales
µg/mLPK Sub-study
500L-FMP77.3 (73.6 to 81.2)
2000L-FMP75.7 (70.7 to 81.0)
PrimaryIndication Expansion: Objective Response Rate

Objective response rate (ORR) is defined as the percentage of participants who achieved objective tumor response (complete response or partial response) according to RECIST Version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.

Time frame:
Up to approximately 3 years and 5 months
Reported as:
Number · Percentage of participants
Indication Expansion: Objective Response Rate
Percentage of participantsTislelizumab
NSCLC17.9 (8.9 to 30.4)
Melanoma17.6 (6.8 to 34.5)
ESCC7.7 (0.9 to 25.1)
GC16.7 (4.7 to 37.4)
UC18.2 (5.2 to 40.3)
NPC47.6 (25.7 to 70.2)
RCC9.5 (1.2 to 30.4)
HCC16.7 (3.6 to 41.4)
MSI-H/dMMR25.0 (7.3 to 52.4)
Other9.5 (3.6 to 19.6)
SecondaryDose Verification: Area Under the Concentration-time Curve From Time 0 to 21 Days Postdose (AUC0-tau) of Tislelizumab
Time frame:
Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 and Cycle 5 (21 days per cycle)
Reported as:
Mean · µg/mL*day
Dose Verification: Area Under the Concentration-time Curve From Time 0 to 21 Days Postdose (AUC0-tau) of Tislelizumab
µg/mL*dayDose Verification
Cycle 1600.1 ± 144.5
Cycle 51122 ± 352
SecondaryDose Verification: Maximum Observed Concentration (Cmax) of Tislelizumab
Time frame:
Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 and Cycle 5 (21 days per cycle)
Reported as:
Mean · µg/mL
Dose Verification: Maximum Observed Concentration (Cmax) of Tislelizumab
µg/mLDose Verification
Cycle 167.8 ± 12.8
Cycle 5131 ± 37.7
SecondaryDose Verification: Predose Plasma Concentration of Tislelizumab During Multiple Dosing (Ctrough)
Time frame:
Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 and Cycle 5 (21 days per cycle)
Reported as:
Mean · µg/mL
Dose Verification: Predose Plasma Concentration of Tislelizumab During Multiple Dosing (Ctrough)
µg/mLDose Verification
Cycle 115.8 ± 4.73
Cycle 531.4 ± 9.55
SecondaryDose Verification: Apparent Terminal Half-life of Tislelizumab (t1/2)
Time frame:
Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 and Cycle 5 (21 days per cycle)
Reported as:
Mean · Days
Dose Verification: Apparent Terminal Half-life of Tislelizumab (t1/2)
DaysDose Verification
Cycle 113.3 ± 2.95
Cycle 516.9 ± 3.79
SecondaryDose Verification: Clearance (Cl)
Time frame:
Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 (21 days per cycle)
Reported as:
Mean · Liters/day
Dose Verification: Clearance (Cl)
Liters/dayDose Verification
Dose Verification: Clearance (Cl)0.247 ± 0.0918
SecondaryIndication Expansion: Progression-free Survival (PFS)

Progression-free survival is defined as the time from the date of first study dose to disease progression or death, whichever comes first, as determined by Investigator per RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.

Time frame:
Up to approximately 3 years and 5 months
Reported as:
Median · Months
Indication Expansion: Progression-free Survival (PFS)
MonthsTislelizumab
NSCLC4.0 (2.1 to 8.1)
Melanoma2.2 (2.0 to 6.1)
ESCC2.1 (2.0 to 4.2)
GC2.1 (1.9 to 4.0)
UC2.1 (2.0 to 4.3)
NPC8.2 (4.2 to 11.4)
RCC4.1 (2.1 to 10.4)
HCC4.0 (2.1 to 12.4)
MSI-H/dMMR6.1 (2.0 to 15.3)
Other2.3 (2.2 to 2.8)
SecondaryIndication Expansion: Duration of Response

Duration of response for responders with complete or partial response is defined as the time interval between the date of the earliest qualifying response and the date of progressive disease or death for any cause, whichever occurs earlier as determined by Investigator per RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.

Time frame:
Up to approximately 3 years and 5 months
Reported as:
Median · Months
Indication Expansion: Duration of Response
MonthsTislelizumab
NSCLC30.4 (8.3 to 30.4)
Melanoma12.5 (4.2 to NA)
ESCCNA (13.8 to NA)
GCNA (13.9 to NA)
UCNA (8.3 to NA)
NPC8.8 (3.9 to 14.8)
RCCNA (4.4 to NA)
HCCNA (8.3 to NA)
MSI-H/dMMRNA (5.1 to NA)
OtherNA (8.3 to NA)
SecondaryIndication Expansion: Clinical Benefit Rate

Clinical benefit rate is defined as the percentage of participants in specific tumor types reaching confirmed CR, PR and durable stable disease (SD; at ≥ 24 weeks) in accordance with RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.

Time frame:
Up to approximately 3 years and 5 months
Reported as:
Number · Percentage of participants
Indication Expansion: Clinical Benefit Rate
Percentage of participantsTislelizumab
NSCLC33.9 (21.8 to 47.8)
Melanoma32.4 (17.4 to 50.5)
ESCC15.4 (4.4 to 34.9)
GC25.0 (9.8 to 46.7)
UC27.3 (10.7 to 50.2)
NPC61.9 (38.4 to 81.9)
RCC38.1 (18.1 to 61.6)
HCC38.9 (17.3 to 64.3)
MSI-H/dMMR50.0 (24.7 to 75.3)
Other22.2 (12.7 to 34.5)
SecondaryIndication Expansion: Overall Survival

Overall survival is defined as the time from the date of the first study dose to death. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.

Time frame:
Up to approximately 3 years and 5 months
Reported as:
Median · Months
Indication Expansion: Overall Survival
MonthsTislelizumab
NSCLC22.1 (10.1 to 33.5)
Melanoma11.8 (7.0 to 24.2)
ESCC4.8 (3.6 to 8.5)
GC4.7 (2.4 to 14.6)
UC4.3 (2.1 to 22.9)
NPC25.0 (11.7 to NA)
RCC19.8 (8.0 to 24.3)
HCC25.1 (5.5 to NA)
MSI-H/dMMR19.4 (4.2 to NA)
Other9.0 (4.8 to 13.4)
SecondaryIndication Expansion: Disease Control Rate

Disease control rate is defined as the percentage of participants reaching CR, PR, and SD according to RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.

Time frame:
Up to approximately 3 years and 5 months
Reported as:
Number · Percentage of participants
Indication Expansion: Disease Control Rate
Percentage of participantsTislelizumab
NSCLC55.4 (41.5 to 68.7)
Melanoma38.2 (22.2 to 56.4)
ESCC34.6 (17.2 to 55.7)
GC25.0 (9.8 to 46.7)
UC40.9 (20.7 to 63.6)
NPC81.0 (58.1 to 94.6)
RCC52.4 (29.8 to 74.3)
HCC55.6 (30.8 to 78.5)
MSI-H/dMMR50.0 (24.7 to 75.3)
Other31.7 (20.6 to 44.7)
SecondaryNumber of Participants With Positive Anti-drug Antibody (ADA) Status to Tislelizumab
Time frame:
Up to approximately 23 months
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-drug Antibody (ADA) Status to Tislelizumab
ParticipantsTislelizumab
Treatment-emergent43
Treatment-boosted2
Treatment-induced41

Adverse events

Collected over Up to 30 days after the last dose of study treatment; Up to approximately 3 years and 5 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tislelizumab202/300 (67.3%)85/300 (28.3%)277/300 (92.3%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventTislelizumab
PneumoniaInfections and infestations11/300
Upper gastrointestinal haemorrhageGastrointestinal disorders6/300
DeathGeneral disorders5/300
Intestinal obstructionGastrointestinal disorders4/300
PyrexiaGeneral disorders3/300
HyperuricaemiaMetabolism and nutrition disorders3/300
DyspnoeaRespiratory, thoracic and mediastinal disorders3/300
Immune-mediated myocarditisCardiac disorders2/300
DysphagiaGastrointestinal disorders2/300
VomitingGastrointestinal disorders2/300
Most frequent other events
Showing 10 of 63
Most frequent other events
EventTislelizumab
AnaemiaBlood and lymphatic system disorders110/300
Aspartate aminotransferase increasedInvestigations81/300
Alanine aminotransferase increasedInvestigations71/300
Blood bilirubin increasedInvestigations52/300
ProteinuriaRenal and urinary disorders52/300
Weight decreasedInvestigations50/300
Gamma-glutamyltransferase increasedInvestigations47/300
HypothyroidismEndocrine disorders45/300
PyrexiaGeneral disorders39/300
Bilirubin conjugated increasedInvestigations37/300

Baseline characteristics

The Safety Analysis Set (SAS) included all participants who received ≥ 1 dose of tislelizumab; Safety analysis data are summarized for the overall population given that the same dose was applied, regardless of part assignment, as pre-specified in the clinical study report.

Age, Continuous
Age, Continuous(Years)Tislelizumab
Mean55.5 ± 11.48
Sex: Female, Male
Sex: Female, Male(Participants)Tislelizumab
Female93
Male207
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tislelizumab
Chinese300
08

Study locations

12 sites
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North)
    Guangzhou, Guangdong 510000, China
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong 510080, China
  • The Fifth Affiliated Hospital Sun Yat Sen University
    Zhuhai, Guangdong 519000, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200000, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai 200032, China
  • Zhejiang University College of Medicine Second Affiliated Hospital
    Hangzhou, Zhejiang 310009, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
09

References and documents

Publications

  • Shen L, Guo J, Zhang Q, Pan H, Yuan Y, Bai Y, Liu T, Zhou Q, Zhao J, Shu Y, Huang X, Wang S, Wang J, Zhou A, Ye D, Sun T, Gao Y, Yang S, Wang Z, Li J, Wu YL. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. J Immunother Cancer. 2020 Jun;8(1):e000437. doi: 10.1136/jitc-2019-000437. Erratum In: J Immunother Cancer. 2020 Jul;8(2):e000437corr1. doi: 10.1136/jitc-2019-000437corr1. PubMed 32561638 ↗
  • Zhou Q et al. Efficacy and safety data from a Phase 1/2 trial of tislelizumab in Chinese patients with non-small cell lung cancer. North America Conference on Lung Cancer, October 2020.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Dec 2018, 23 months.

Results were first posted in Nov 2023, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2019
First posted
Aug 28, 2019
StartActual
Dec 28, 2016
Primary completionActual
Dec 1, 2018
CompletionActual
May 31, 2020
Results first posted
Nov 30, 2023
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04068519
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Dec 28, 2016
Primary completion
Dec 1, 2018
Completion
May 31, 2020
Results posted
Nov 30, 2023
Last update
Oct 26, 2024

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion